EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/article/10.1007/s11060-019-03102-5/fulltext.html
Reference29 articles.
1. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844. https://doi.org/10.1038/362841a0
2. Ferrara N, Adamis AP (2016) Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15(6):385. https://doi.org/10.1038/nrd.2015.17
3. Thomas AA, Brennan CW, DeAngelis LM, Omuro AM (2014) Emerging therapies for glioblastoma. JAMA Neurol 71(11):1437–1444. https://doi.org/10.1001/jamaneurol.2014.1701
4. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708. https://doi.org/10.1056/NEJMoa1308573
5. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722. https://doi.org/10.1056/NEJMoa1308345
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Insights into brain tumor diagnosis: exploring in situ hybridization techniques;Frontiers in Neurology;2024-07-03
2. Bevacizumab for Glioblastoma Multiforme: A Literature Review;JAP Academy Journal;2024-06-01
3. Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study;AVICENNA J PHYTOMEDI;2024
4. A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy;Discover Oncology;2024-03-22
5. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies;Journal of Experimental & Clinical Cancer Research;2023-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3